Axogen, inc. announces positive topline results from repose, a prospective, randomized clinical trial of axoguard nerve cap

Repose® met its primary endpoint of non-inferiority between the pain visual analog scale outcomes for neurectomy with axoguard nerve cap® vs. standard-of-care neurectomy at month 12.

AXGN Ratings Summary

AXGN Quant Ranking